Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.54 |
| ▸ | EGFR | P00533 | 10/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 2/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30638113 | 1.00 | ABCG2 (0.54) | ABCG2EGFRFYNSRCFBP1 | |
| SCHEMBL30638097 | 0.88 | EGFR (0.59) | ABCG2EGFRFBP1 | |
| SCHEMBL157043 | 0.88 | EGFR (0.59) | ABCG2EGFRFBP1 | |
| SCHEMBL26321 | 0.87 | EGFR (0.64) | ABCG2EGFRFBP1 | |
| SCHEMBL31472871 | 0.85 | EGFR (0.58) | ABCG2EGFRFBP1 | |
| SCHEMBL15391257 | 0.85 | EGFR (0.58) | ABCG2EGFRFBP1 | |
| SCHEMBL15050338 | 0.84 | EGFR (0.71) | ABCG2EGFRSRCFBP1 | |
| SCHEMBL4579486 | 0.83 | EGFR (0.56) | ABCG2EGFRFBP1 | |
| SCHEMBL25241 | 0.83 | EGFR (0.63) | EGFRFBP1 | |
| SCHEMBL28413582 | 0.83 | EGFR (0.59) | ABCG2EGFRFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655599-A | Synthesis and application of EGFR allosteric inhibitors | 江南大学 | 2023-08-29 | — | — | CN | disclosed |
| EP-2611797-B1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO LTD (KR) | 2016-12-28 | — | — | EP | disclosed |
| US-8835458-B2 | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | HANMI SCIENCE CO., LTD (KR) | 2014-09-16 | — | — | US | disclosed |
| EP-2611797-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | Hanmi Science Co., Ltd. (KR) | 2013-07-10 | — | — | EP | disclosed |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO., LTD (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012030160-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI HOLDINGS CO., LTD. (KR) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | CASP7, API5, BAX | ABCG2 2153/4885EGFR 4690/4885FYN 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.